Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection
| Autor: | Zhixiao Ding, Shixiong Liang, Ailu Wu, Xiaoting Song, Chunyan Zhang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine China Hepatitis B virus Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis Hepatocellular carcinoma medicine.disease_cause Chronic liver disease Gastroenterology 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Proto-Oncogene Proteins Internal medicine Diagnosis Biomarkers Tumor Humans Medicine neoplasms Retrospective Studies Receiver operating characteristic business.industry Liver Neoplasms Receptor Protein-Tyrosine Kinases Biomarker Middle Aged Soluble Axl Prognosis medicine.disease Axl Receptor Tyrosine Kinase digestive system diseases Confidence interval 030104 developmental biology ROC Curve Oncology Case-Control Studies 030220 oncology & carcinogenesis Biomarker (medicine) Female Original Article alpha-Fetoproteins Differential diagnosis business Follow-Up Studies |
| Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| ISSN: | 2005-9256 1598-2998 |
| Popis: | PurposeThe purpose of this study was to evaluate the diagnostic value of soluble Axl (sAxl) in hepatocellular carcinoma (HCC) in comparison with serum α-fetoprotein (AFP).Materials and MethodsEighty HCC patients, 80 liver cirrhosis patients (LC), 80 patients with hepatitis B virus (HBV) infection, and 80 healthy controls (HC) were enrolled. sAxl levels were measured by an enzyme-linked immunosorbent assay, serum AFP levelswere measured by an electrochemiluminescence immunoassay. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performances.ResultsThe results show that levels of sAxl were high expression in patients with HCC (p < 0.05), varied with disease state as follows: HCC > LC > HC > HBV. Logistic regression and ROC curve analysis identified the optimal cut-off for sAxl in differentiating all HCC and non-HCC patients was 1,202 pg/mL (area under the receiver operating characteristic [AUC], 0.888; 95% confidence interval [CI], 0.852 to 0.924) with sensitivity 95.0%, specificity 73.3%. Furthermore, differential diagnosis of early HCC with non-HCC patients for sAxl showed the optimal cut-off was 1,202 pg/mL (AUC, 0.881; 95% CI, 0.831 to 0.931; sensitivity, 94.1%; specificity, 73.3%). Among AFP-negative HCC patients with non-HCC patients, the cut-off was 1,301 pg/mL (AUC, 0.898; 95% CI, 0.854 to 0.942) with a sensitivity of 84.6%, a specificity of 76.3%. The optimal cut-off for sAxl in differentiating all HCC and chronic liver disease patients was 1,243 pg/mL (AUC, 0.840; 95% CI, 0.791 to 0.888) with sensitivity 93.8%, specificity 61.9%. The combination of AFP and sAxl increased diagnostic value for HCC.ConclusionsAxl outperforms AFP in detecting HCC, especially in early HCC and in AFP-negative HCC. Combination sAxl with AFP improved the specificity for early HCC diagnosis. In summary, sAxl is a candidate serum marker for diagnosing HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|